Topic: Absolute Risk Reduction

Gavi is reportedly ordering 18 million doses of malaria vaccines despite a lack of current demand, anticipating a 100 million dose annual requirement by 2030. Attorney Tom Renz cites NIH data showing that the absolute risk reduction for these malaria vaccines is as low as 1.1%. The study results are characterized as statistical garbage designed to justify the release of genetically modified mosquitoes.

The FDA's approval of the new bivalent COVID-19 booster is criticized for being based on a study involving only eight mice rather than comprehensive human trials. Dr. Alexander notes that Pfizer's original data showed a much lower absolute risk reduction than the 95% relative risk reduction advertised. He concludes that the relationship between pharmaceutical companies and federal regulatory agencies has become collusive and fraudulent.

An analysis of Pfizer's Emergency Use Authorization (EUA) data reveals that the "95% efficacy" is a relative measure, while the absolute risk reduction is only 0.88%. Dr. Fleming asserts that when statistically analyzed, there is no significant difference in COVID-19 cases or deaths between the vaccinated and unvaccinated groups in the original study.

Dr. Richard Fleming analyzes data from 33 countries, including Israel and Singapore, showing that COVID-19 cases and deaths often increase following mass vaccination campaigns. He points out that the "absolute risk reduction" for the Pfizer vaccine was only 0.88%. Fleming argues that the vaccinated are the ones driving the creation of new variants through pressure selection.